Talonavicular Arthrodesis and Surgical Treatment of Ankle and Varus Foot

Orthopedic Equine Varus Deformity Clinical Trial

— talobot  

Official title:

Interest of Talonavicular Arthrodesis on Walking Speed at Brain Lesion Patients Who Benefit of a Surgical Treatment of Ankle and Varus Foot : Randomized Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02790346
• Other study ID #: 9547
• Status: Completed
• Phase: N/A
• Start date: December 2015
• Est. completion date: June 27, 2023

Study information

• Verified date: March 2024
• Source: University Hospital, Montpellier
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study should refine our surgical indications and to establish a decision tree of medical and surgical treatment of this common and troublesome strain functionally which is equino-varus.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 33
• Est. completion date: June 27, 2023
• Est. primary completion date: June 27, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 74 Years

Eligibility

Inclusion Criteria:

• Hemiparesis secondary to a lesion of the central nervous system, regardless of the etiology dated within 6 months

• Orthopedic equine-varus deformity of the foot and ankle requiring surgery

• Patient able to move by walking preoperatively at least 2 meters with or without technical assistance or may earn postoperative walking ability

Exclusion Criteria:

• History of foot surgery the side to be operated

• Significant deformation set foot and ankle (requiring treatment with triple arthrodesis)

• Bilateral surgery

• Progressive neurological disease

• Dystonic movements or movement disorders

• Realization of a botulinum toxin injection in the 6 months preceding gesture

• Important cognitive impairment

Related Conditions & MeSH terms

• Congenital Abnormalities
• Orthopedic Equine Varus Deformity

Intervention

Procedure:
• arthrodesis talonavicular

• tendon gestures

Locations

Country	Name	City	State
France	CHRU Lapeyronie	Montpellier	Herault

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	walking speed at one year		12 months after surgery intervention
Secondary	walking speed at 3 and 6 months		3 months and 6 months after surgery intervention